FDA warns against relying antigen rapid qualitative test

Please share this story - thanks

Press release

The U.S. Food and Drug Administration (FDA) is warning the public to stop using the Innova Medical Group SARS-CoV-2 Antigen Rapid Qualitative Test for diagnostic use.

The FDA has significant concerns that the performance of the test has not been adequately established, presenting a risk to health. In addition, labeling distributed with certain configurations of the test includes performance claims that did not accurately reflect the performance estimates observed during the clinical studies of the tests.

Finally, the test has not been authorized, cleared, or approved by the FDA for commercial distribution or use in the United States, as required by law.

The Innova Medical Group SARS-CoV-2 Antigen Rapid Qualitative Test is also distributed under the names Innova COVID-19 Self-Test Kit (3T Configuration), Innova Medical Group SARS-CoV-2-Antigen Rapid Qualitative Test (7T Configuration), and Innova Medical Group SARS-CoV-2-Antigen Rapid Qualitative Test (25T Configuration).

On April 23, 2021, Innova Medical Group recalled their Innova Medical Group SARS-CoV-2 Antigen Rapid Qualitative Test. The FDA has identified this recall as a Class I recall, the most serious type of recall.

Source here.

Please share this story - thanks